The Drive to Discover. The Experience to Deliver.
INCYTE
Incyte 2012 Annual Report
to Stockholders Jakafi® (ruxolitinib)
Prescribing Information
to Stockholders Jakafi® (ruxolitinib)
Prescribing Information
is a biopharmaceutical company focused on discovering, developing and commercializing proprietary small molecule drugs for oncology and inflammation.
News
Incyte Drug Jakafi® (ruxolitinib) Improved Overall Survival in Phase III Trial of Patients with Myelofibrosis
Lilly and Incyte Announce Baricitinib Efficacy and Safety Data from the Open-Label, Long-Term Extension of the Phase 2b JADA Study in Patients with Rheumatoid Arthritis
Jakafi® (ruxolitinib) Prescribing Information Updated with Expanded Dosing Guidance and New Safety Information
Jakafi® (ruxolitinib)
IncyteCARES
Connecting to Access, Reimbursement, Education and Support
To learn more, click here
To learn more, click here